Trials / Completed
CompletedNCT00425555
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panobinostat |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2007-01-23
- Last updated
- 2021-08-20
- Results posted
- 2021-08-16
Locations
42 sites across 12 countries: United States, Argentina, Australia, Belgium, Canada, Finland, France, Germany, Hungary, Italy, Spain, Switzerland
Source: ClinicalTrials.gov record NCT00425555. Inclusion in this directory is not an endorsement.